Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Entrada Therapeutics, Inc.

NASDAQ: TRDA · Life Sciences · 2 alerts · CIK 1689375

Share price
$5.00Close, Nov 16
Market cap
$196M
Shares outstanding
39.15MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Entrada Therapeutics, Inc. filings on SEC EDGAR ↗

7:07 AM ET 8-K
Financial Results

Entrada Therapeutics Financial Results

Entrada Therapeutics reported third quarter 2026 financial results and provided updates on its clinical pipeline, including its ELEVATE-44-201 and ELEVATE-45-201 programs for Duchenne muscular dystrophy. The company ended the quarter with $193 million in cash, extending its expected runway into Q4 2027. Multiple clinical data readouts are expected through the first half of 2027, including data from its DM1 partnership with Vertex.

“The October Cohort 1 data from ELEVATE-45-201 marked our third consecutive readout demonstrating encouraging safety and tolerability across our clinical programs. With these initial dose cohorts supporting the safety profile of our lead Duchenne programs, our attention now turns to the next set of readouts designed to further define the potential of our investigational medicines.”

Dipal Doshi, Chief Executive Officer of Entrada Therapeutics

“Including the anticipated Phase 1/2 clinical data from our partner Vertex’s GALILEO study in myotonic dystrophy type 1 during the second half of 2026, we expect four clinical data readouts through the first half of 2027. This marks an important period of clinical catalysts for Entrada as we advance our pipeline and work toward our goal of delivering potentially transformative medicines to people living with serious neuromuscular diseases.”

Dipal Doshi, Chief Executive Officer of Entrada Therapeutics
7:52 AM ET 8-K
Clinical Trial Data

Entrada Therapeutics Clinical Trial Data

Entrada Therapeutics announced positive topline data from Cohort 1 of its Phase 1/2 ELEVATE-45-201 study evaluating ENTR-601-45 in patients with Duchenne Muscular Dystrophy (DMD). The study met its primary objectives of favorable safety and tolerability at the 5 mg/kg dose, with secondary objectives showing a 0.10% mean increase in dystrophin production. The company is currently dosing Cohort 2 at 10 mg/kg and expects to report data from that cohort in the first half of 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.